Penumbra (PEN) Net Income towards Common Stockholders (2014 - 2026)
Penumbra (PEN) posted quarterly Net Income towards Common Stockholders of $34.8 million for Q2 2026, down 23.16% year-over-year from $45.3 million in Q2 2025, and up 6.76% quarter-over-quarter from $32.6 million in Q1 2026.
Penumbra (PEN) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Net Income towards Common Stockholders for 13 consecutive years, with $34.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders fell 23.16% year-over-year to $34.8 million; the TTM figure through Jun 2026 stood at $160.5 million (up 8.73% YoY), while the FY2025 annual figure was $177.7 million, up 1168.11% from the prior year.
- Net Income towards Common Stockholders improved to $34.8 million in Q2 2026 per PEN's latest filing, from $32.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $54.2 million in Q4 2023 and bottomed at -$60.2 million in Q2 2024.
- Historically, Net Income towards Common Stockholders has averaged $19.3 million across 5 years, with a median of $24.2 million in 2023.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 10725.32% — and 2024, when it sank 417.78%.
- Penumbra's Net Income towards Common Stockholders stood at $3.9 million in 2022, then soared by 1298.45% to $54.2 million in 2023, then plunged by 37.88% to $33.7 million in 2024, then jumped by 40.56% to $47.3 million in 2025, then dropped by 26.52% to $34.8 million in 2026.
- Business Quant data shows PEN's Net Income towards Common Stockholders at $34.8 million in Q2 2026, $32.6 million in Q1 2026, and $47.3 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Penumbra | 12.78 Bn | 12.12 Bn | 264.94 Mn | 34.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.79 Mn |
| Mar 31, 2026 | 32.59 Mn |
| Dec 31, 2025 | 47.34 Mn |
| Sep 30, 2025 | 45.85 Mn |
| Jun 30, 2025 | 45.31 Mn |
| Mar 31, 2025 | 39.22 Mn |
| Dec 31, 2024 | 33.68 Mn |
| Sep 30, 2024 | 29.48 Mn |
| Jun 30, 2024 | -60.20 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 54.22 Mn |
| Sep 30, 2023 | 9.21 Mn |
| Jun 30, 2023 | 18.94 Mn |
| Mar 31, 2023 | 8.56 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -3.69 Mn |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | -24.63 Mn |
| Sep 30, 2021 | 8.03 Mn |